Skip to main content

Market Overview

UPDATE: Barclays Capital Initiates Coverage On Alexion Pharmaceuticals On Compelling Factors Ahead

Share:

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) with an Overweight rating and $225.00 price target.

In the report, Barclays Capital noted, “Alexion's Soliris franchise has shown no signs of moderating and in 2015, a positive label update for aHUS and newer launch geographies could drive upside to the consensus of ~23% growth. 2015 is also expected to bring the approval / launch of asfotase alfa in the US / EU / Japan for HPP (hypophosphatasia), which we think is nearly a $1.5B peak indication, above current consensus forecasts. In the pipeline, de-risking data for Soliris in AMR (antibody-mediated rejection) in 2H15 should set up the next Soliris indication / launch, which isn't assumed in our model and the majority of Street models. Based on continued strong execution for Soliris, the launch of asfostase (which diversifies the revenue mix) and a number of meaningful pipeline catalysts, we think that Alexion is setting up for a strong 2015. Hence, we're initiating coverage with an Overweight rating and $225 target.”

Alexion Pharmaceuticals closed on Monday at $182.17.

Latest Ratings for ALXN

DateFirmActionFromTo
Mar 2021SVB LeerinkDowngradesOutperformMarket Perform
Feb 2021SVB LeerinkMaintainsOutperform
Jan 2021Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Price Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com